EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Ralph Tiedt, Frederick J King, Christelle Stamm, Matthew J Niederst, Scott Delach, Sabine Zumstein-Mecker, Jodi Meltzer, Iain J Mulford, Emma Labrot, Barbara Schacher Engstler, Sabrina Baltschukat, Grainne Kerr und 9 weitere

Cell Reports · 2023-04 · 42 (4) · 112297

DOI: 10.1016/j.celrep.2023.112297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023-04. Verfasst von Ralph Tiedt und 20 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Institutes for BioMedical Research Basel, Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansProto-Oncogene Proteins B-rafClustered Regularly Interspaced Short Palindromic RepeatsNeoplasm Recurrence, LocalProtein Kinase InhibitorsErbB ReceptorsReceptor Protein-Tyrosine KinasesMitogen-Activated Protein Kinase KinasesMutationCell Line, Tumor

Stichwörter der Autor:innen

ALK-translocated lung cancerBRAF-mutant colorectal cancerCP: CancerCRISPR screenEGFR-mutant lung cancercombinationsdrug screentargeted therapy

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsErbB ReceptorsReceptor Protein-Tyrosine KinasesMitogen-Activated Protein Kinase KinasesBRAF protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland.
  • Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA.
  • Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com.
  • Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA.

Förderung

  • Novartis Institutes for BioMedical Research Basel
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., Baltschukat, S., Kerr, G., Golji, J., Wyss, D., Schnell, C., Ainscow, E., Engelman, J. A., Sellers, W. R., Barretina, J., …, & Porta, D. G. (2023). Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports, 42(4), 112297. https://doi.org/10.1016/j.celrep.2023.112297

Vancouver

Tiedt R, King FJ, Stamm C, Niederst MJ, Delach S, Zumstein-Mecker S, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Reports. 2023;42(4):112297. doi:10.1016/j.celrep.2023.112297

BibTeX
@article{Tiedt2023,
  author = {Tiedt, Ralph and King, Frederick J and Stamm, Christelle and Niederst, Matthew J and Delach, Scott and Zumstein-Mecker, Sabine and Meltzer, Jodi and Mulford, Iain J and Labrot, Emma and Engstler, Barbara Schacher and Baltschukat, Sabrina and Kerr, Grainne and Golji, Javad and Wyss, Daniel and Schnell, Christian and Ainscow, Edward and Engelman, Jeffrey A and Sellers, William R and Barretina, Jordi and Caponigro, Giordano and Porta, Diana Graus},
  title = {Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {4},
  pages = {112297},
  doi = {10.1016/j.celrep.2023.112297}
}
Kostenlos starten →